Last updated: November 16, 2023
Sponsor: University Hospital Augsburg
Overall Status: Active - Recruiting
Phase
N/A
Condition
Metastatic Cancer
Neuroblastoma
Neoplasm Metastasis
Treatment
N/AClinical Study ID
NCT05245136
N67
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Written informed consent
- Age ≥ 18 years
- Histopathologically confirmed metastatic or locally advanced cancer
- No curative treatment options, except for germ cell tumors
- Written Agreement to be followed up at Augsburg University Medical Center
- Signed written informed consent for the Biobank Augsburg (Biobank-A)
- Willing to undergo treatment according to standard of care
- Availability or anticipated availability of tumor tissue at time point of inclusion
- Anticipated life expectancy of at least 3 months at time point of trial inclusion
Exclusion
Exclusion Criteria:
- Psychological condition that would preclude informed consent
- Additional tumor treatment between acquisition of tumor tissue and trial inclusion
Study Design
Total Participants: 3000
Study Start date:
March 29, 2021
Estimated Completion Date:
April 30, 2025
Study Description
Connect with a study center
University Hospital Augsburg
Augsburg, Bavaria 86156
GermanyActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.